Topical dermatological formulations and use thereof

Details Topical dermatological formulations and use thereof Topical dermatological formulations and use thereof

2011-03-01

2011-03-01

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S179000, C552S500000

Reexamination Certificate

active

07897587

ABSTRACT:
A topical formulation of an androstane steroid compound of improved solubility in combinations of the solvents propylene glycol and propylene carbonate.

REFERENCES:
patent: 4017615 (1977-04-01), Shastri et al.
patent: 4233295 (1980-11-01), Hill et al.
patent: 4393076 (1983-07-01), Noda et al.
patent: 5993787 (1999-11-01), Sun et al.
patent: 6479058 (2002-11-01), McCadden
patent: 6656928 (2003-12-01), McCadden
patent: 6765001 (2004-07-01), Gans et al.
patent: 2002/0032149 (2002-03-01), Kensey
patent: 2002/0192273 (2002-12-01), Buseman et al.
patent: 2003/0073676 (2003-04-01), Biggadike et al.
patent: 2003/0077316 (2003-04-01), Nichols et al.
patent: 2003/0078517 (2003-04-01), Kensey
patent: 2003/0149029 (2003-08-01), McKew
patent: 2003/0176408 (2003-09-01), Gans et al.
patent: 2003/0186951 (2003-10-01), Gans et al.
patent: WO 00/24401 (2000-05-01), None
patent: WO02/13868 (2002-02-01), None
R.B. Stoughton, “Vasoconstrictor Assay-Specific Applications”,pp. 42-53, Topical Corticosteroids, Maibach and Surber (eds),Basel 1992.

Affiliated with

Also associated with

Rating

Topical dermatological formulations and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical dermatological formulations and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical dermatological formulations and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2725973